Encoded Raises $275 Million for ETX101 Pivotal Development

Evidence Source-gap catch-up · Published September 9, 2026 · Discovery September 9, 2026 · Importance 5/5 · Direction Positive Summary Encoded Therapeutics closed a $275 million Series F financing to fund pivotal development of ETX101 in SCN1A-positive Dravet syndrome, expand development through age 18, scale…